Hatice Terzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hatice Terzi has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Mehmet Sencan
Department of Internal Medicine, Department of Hematology, Faculty of Medicine, Sivas Cumhuriyet University, 58140 Sivas, Türkiye
11 shared publications - Serdal Korkmaz
University of Health Sciences, Kayseri Training and Research Hospital, Department of Hematology, Kayseri, Turkey
5 shared publications Mehmet Şencan
Division of Hematology Department of Internal Medicine Sivas Cumhuriyet University Faculty of Medicine Sivas Türkiye
3 shared publications- Muzaffer Keklik
Department of Hematology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
3 shared publications - Ecem Demir
Department of Statistics and Computer Sciences, Faculty of Science, Sivas Cumhuriyet University, Sivas, Türkiye
2 shared publications - Fevzi Altuntaş
Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey
2 shared publications
Latest Publications
- Open Access
- 26 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8611
Immunohistochemical Classification and Prognostic Significance of Germinal Center-like and Memory Cell-like Subtypes of Follicular Lymphoma Using FOXP1, LMO2, CD22, and MUM1
Follicular lymphoma (FL) is an indolent B-cell lymphoma with considerable biological and clinical heterogeneity, highlighting the need for additional prognostic biomarkers beyond conventional clinicopathological parameters. This study aimed to evaluate the prognostic significance of an immunohistochemical classification separating FL into a germinal center-like (GC-like) phenotype, characterized by retention of germinal-center-associated features, and a memory-like (Mem-like) phenotype, reflecting a more differentiated post-germinal-center/memory B-cell state. Fifty-one patients with FL were retrospectively analyzed for clinicopathological characteristics, immunohistochemical findings, relapse, and overall survival (OS). LMO2 expression was detected in 70.6% of cases and was associated with lower mortality (19.4% vs. 60.0%, p = 0.008), lower relapse rates (8.3% vs. 33.3%, p = 0.039), and improved 5-year OS (85.3% vs. 35.0%, log-rank p = 0.003). FOXP1 positivity was observed in 41.2% of cases and was associated with higher mortality (57.1% vs. 13.3%, p = 0.002) and inferior 5-year OS (44.5% vs. 89.4%, log-rank p < 0.001). Mem-like patients had significantly poorer 5-year OS than GC-like patients (39.5% vs. 90.1%, log-rank p < 0.001). These findings suggest that LMO2 and FOXP1 expression may provide complementary prognostic information and help identify clinically distinct immunophenotypic subsets in FL.
- 26 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8611
Open AccessImmunohistochemical Classification and Prognostic Significance of Germinal Center-like and Memory Cell-like Subtypes of Follicular Lymphoma Using FOXP1, LMO2, CD22, and MUM1
Follicular lymphoma (FL) is an indolent B-cell lymphoma with considerable biological and clinical heterogeneity, highlighting the need for additional prognostic biomarkers beyond conventional clinicopathological parameters. This study aimed to evaluate the prognostic significance of an immunohistochemical classification separating FL into a germinal center-like (GC-like) phenotype, characterized by retention of germinal-center-associated features, and a memory-like (Mem-like) phenotype, reflecting a more differentiated post-germinal-center/memory B-cell state. Fifty-one patients with FL were retrospectively analyzed for clinicopathological characteristics, immunohistochemical findings, relapse, and overall survival (OS). LMO2 expression was detected in 70.6% of cases and was associated with lower mortality (19.4% vs. 60.0%, p = 0.008), lower relapse rates (8.3% vs. 33.3%, p = 0.039), and improved 5-year OS (85.3% vs. 35.0%, log-rank p = 0.003). FOXP1 positivity was observed in 41.2% of cases and was associated with higher mortality (57.1% vs. 13.3%, p = 0.002) and inferior 5-year OS (44.5% vs. 89.4%, log-rank p < 0.001). Mem-like patients had significantly poorer 5-year OS than GC-like patients (39.5% vs. 90.1%, log-rank p < 0.001). These findings suggest that LMO2 and FOXP1 expression may provide complementary prognostic information and help identify clinically distinct immunophenotypic subsets in FL.
- Open Access
- 22 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4657
Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies
Hematologic malignancies are driven by dysregulated growth and survival signaling pathways that promote proliferation, treatment resistance, and disease progression. Naturally derived compounds targeting multiple oncogenic pathways with low toxicity have gained interest. Apigenin, a dietary flavonoid, shows anticancer activity in solid tumors, but its molecular effects in hematologic malignancies remain unclear. The antineoplastic effects of apigenin were evaluated in K562 (chronic myeloid leukemia) and DOHH2 (B-cell lymphoma) cell lines. Cell viability was assessed using the CCK-8 assay. L929 (mouse fibroblast) cells were included to evaluate selectivity. EGFR, MAPK, PI3K, NF-κB, caspase-3, and caspase-7 levels were measured by ELISA. Apoptosis and cell cycle distribution were analyzed by flow cytometry. Apigenin reduced cell viability in a dose-dependent manner, with IC50 values of 84.14 μM (K562) and 70.11 μM (DOHH2). It suppressed EGFR, MAPK, PI3K, and NF-κB signaling and increased the caspase-3 and caspase-7 levels (p < 0.001). Flow cytometry showed S-phase arrest and increased apoptosis. L929 cells showed limited reduction in viability at higher concentrations. Apigenin exerts antiproliferative and pro-apoptotic effects via inhibition of the EGFR/MAPK and PI3K/Akt pathways and activation of caspase-mediated apoptosis. Lower sensitivity in L929 cells suggests relative selectivity, supporting further in vivo and clinical studies.
- 22 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4657
Open AccessApigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies
Hematologic malignancies are driven by dysregulated growth and survival signaling pathways that promote proliferation, treatment resistance, and disease progression. Naturally derived compounds targeting multiple oncogenic pathways with low toxicity have gained interest. Apigenin, a dietary flavonoid, shows anticancer activity in solid tumors, but its molecular effects in hematologic malignancies remain unclear. The antineoplastic effects of apigenin were evaluated in K562 (chronic myeloid leukemia) and DOHH2 (B-cell lymphoma) cell lines. Cell viability was assessed using the CCK-8 assay. L929 (mouse fibroblast) cells were included to evaluate selectivity. EGFR, MAPK, PI3K, NF-κB, caspase-3, and caspase-7 levels were measured by ELISA. Apoptosis and cell cycle distribution were analyzed by flow cytometry. Apigenin reduced cell viability in a dose-dependent manner, with IC50 values of 84.14 μM (K562) and 70.11 μM (DOHH2). It suppressed EGFR, MAPK, PI3K, and NF-κB signaling and increased the caspase-3 and caspase-7 levels (p < 0.001). Flow cytometry showed S-phase arrest and increased apoptosis. L929 cells showed limited reduction in viability at higher concentrations. Apigenin exerts antiproliferative and pro-apoptotic effects via inhibition of the EGFR/MAPK and PI3K/Akt pathways and activation of caspase-mediated apoptosis. Lower sensitivity in L929 cells suggests relative selectivity, supporting further in vivo and clinical studies.
- Open Access
- 26 May 2025
- Published by MediHealth Academy in Intercontinental Journal of Internal Medicine
- Vol. 3 (2) , 30-35
Evaluation of the impact of nutritional parameters on mortality in patients with multiple myeloma
Aims: Multiple myeloma (MM) is a type of cancer originating in plasma cells. While it can be managed with treatment, it is typically not curable. Recent research has underscored the significance of nutritional factors in forecasting the prognosis of patients with MM. This study aims to investigate the impact of nutritional indicators on mortality among patients diagnosed with multiple myeloma. Methods: We performed a retrospective study to analyze overall survival (OS) in 225 patients with MM, focusing on the association between the controlling nutritional status (CONUT) score, the Geriatric Nutritional Risk Index (GNRI), and patient outcomes. Results: Of the patients, 69 (30.7%) were younger than 65, while 156 (69.3%) were aged 65 years or older. The impact of CONUT scores on OS was statistically significant, particularly in patients aged 65 years and older (p=0.042). Among patients who had undergone autologous peripheral blood stem cell transplantation (Auto-PBSCT), a statistically significant correlation was observed between GNRI scores and survival times (p=0.002). Our results suggest improving patients’ nutritional status positively influences treatment outcomes and survival rates. Conclusion: The efficacy of nutritional scores on survival in MM has been demonstrated. We recommend clinicians assess patients’ nutritional status when developing treatment plans and consider implementing appropriate nutritional interventions.
- 26 May 2025
- Published by MediHealth Academy in Intercontinental Journal of Internal Medicine
- Vol. 3 (2) , 30-35
Open AccessEvaluation of the impact of nutritional parameters on mortality in patients with multiple myeloma
Aims: Multiple myeloma (MM) is a type of cancer originating in plasma cells. While it can be managed with treatment, it is typically not curable. Recent research has underscored the significance of nutritional factors in forecasting the prognosis of patients with MM. This study aims to investigate the impact of nutritional indicators on mortality among patients diagnosed with multiple myeloma. Methods: We performed a retrospective study to analyze overall survival (OS) in 225 patients with MM, focusing on the association between the controlling nutritional status (CONUT) score, the Geriatric Nutritional Risk Index (GNRI), and patient outcomes. Results: Of the patients, 69 (30.7%) were younger than 65, while 156 (69.3%) were aged 65 years or older. The impact of CONUT scores on OS was statistically significant, particularly in patients aged 65 years and older (p=0.042). Among patients who had undergone autologous peripheral blood stem cell transplantation (Auto-PBSCT), a statistically significant correlation was observed between GNRI scores and survival times (p=0.002). Our results suggest improving patients’ nutritional status positively influences treatment outcomes and survival rates. Conclusion: The efficacy of nutritional scores on survival in MM has been demonstrated. We recommend clinicians assess patients’ nutritional status when developing treatment plans and consider implementing appropriate nutritional interventions.
- 15 May 2025
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 25 (7) , 1-10
Evaluation of the Antitumoral Effect of PI3K/AKT/mTOR Pathway Inhibition and Antioxidant Combination on Burkitt Lymphoma Cell Line
Background and Aim: Burkitt lymphoma is a highly aggressive type of B-cell non-Hodgkin lymphoma. While it is more commonly seen in children and adolescents, it ac-counts for about 1-2% of adult lymphomas. Since it has high Ki-67 ratios, both its progres-sion rate and sensitivity to chemotherapy are high. However, treatment success decreases in chemotherapy-resistant relapsed/refractory groups. Therefore, new and less toxic therapeutic agents targeting biological pathways related to Burkitt lymphoma pathogenesis are needed. In our study, we aimed to determine the antitumoral efficacy of PI3K/AKT/mTOR pathway inhibitor ETP 45658 and antioxidant Resveratrol, which play a role in Burkitt lymphoma pathogenesis on a Burkitt lymphoma cell line. Methods: Burkitt lymphoma Raji cell line was used in our study. ETP 45658 was applied to the cell line at concentrations of 50, 25, 12.5, 1, 0.1, and 0.01 µM, both alone and in combi-nation with 100 µM resveratrol. The cytotoxic effects of ETP 45658 and the combination treatment on Raji cells were then evaluated using an in vitro XTT cell viability test. IC50 value was calculated according to the results obtained in the XTT test. Based on the IC50 value, the apoptosis assay was studied using the flow cytometry method. Results: Our research showed that increasing doses of ETP 45658, individually and in com-bination, had a statistically significant cytotoxic effect on Burkitt lymphoma Raji cells. This cytotoxic effect was found to be higher in combination treatment. In apoptosis experiments with the calculated IC50 value, it induced apoptosis weakly. Conclusion: Our study showed that ETP 45668 alone and in combination with resveratrol has antitumoral activity on the Burkitt lymphoma cell line. PI3K/Akt/mTOR pathway in-hibitors may be an alternative treatment option in patients with relapsed/refractory Burkitt lymphoma. However, more preclinical and clinical studies are needed.
- 15 May 2025
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 25 (7) , 1-10
Evaluation of the Antitumoral Effect of PI3K/AKT/mTOR Pathway Inhibition and Antioxidant Combination on Burkitt Lymphoma Cell Line
Background and Aim: Burkitt lymphoma is a highly aggressive type of B-cell non-Hodgkin lymphoma. While it is more commonly seen in children and adolescents, it ac-counts for about 1-2% of adult lymphomas. Since it has high Ki-67 ratios, both its progres-sion rate and sensitivity to chemotherapy are high. However, treatment success decreases in chemotherapy-resistant relapsed/refractory groups. Therefore, new and less toxic therapeutic agents targeting biological pathways related to Burkitt lymphoma pathogenesis are needed. In our study, we aimed to determine the antitumoral efficacy of PI3K/AKT/mTOR pathway inhibitor ETP 45658 and antioxidant Resveratrol, which play a role in Burkitt lymphoma pathogenesis on a Burkitt lymphoma cell line. Methods: Burkitt lymphoma Raji cell line was used in our study. ETP 45658 was applied to the cell line at concentrations of 50, 25, 12.5, 1, 0.1, and 0.01 µM, both alone and in combi-nation with 100 µM resveratrol. The cytotoxic effects of ETP 45658 and the combination treatment on Raji cells were then evaluated using an in vitro XTT cell viability test. IC50 value was calculated according to the results obtained in the XTT test. Based on the IC50 value, the apoptosis assay was studied using the flow cytometry method. Results: Our research showed that increasing doses of ETP 45658, individually and in com-bination, had a statistically significant cytotoxic effect on Burkitt lymphoma Raji cells. This cytotoxic effect was found to be higher in combination treatment. In apoptosis experiments with the calculated IC50 value, it induced apoptosis weakly. Conclusion: Our study showed that ETP 45668 alone and in combination with resveratrol has antitumoral activity on the Burkitt lymphoma cell line. PI3K/Akt/mTOR pathway in-hibitors may be an alternative treatment option in patients with relapsed/refractory Burkitt lymphoma. However, more preclinical and clinical studies are needed.
- Open Access
- 30 April 2025
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 27 (1) , 23-28
Determination of Serum Interleukin-36 Alpha, Beta, Gamma, and Interleukin-17 Levels in Patients with Non-Hodgkin Lymphoma
Aim: Non-Hodgkin lymphoma (NHL) is a diverse group of hematologic cancers characterized by uncontrolled proliferation of lymphoid cells. This study aimed to evaluate the relationship between serum concentrations of interleukin-36 alpha (IL-36α), interleukin-36 beta (IL-36β), interleukin-36 gamma (IL-36γ), and interleukin-17 (IL-17), which play an important role in the immune system, in NHL patients and whether these cytokines can serve as potential biomarkers or therapeutic targets for NHL. Material and Methods: A total of 88 individuals, including 55 NHL patients diagnosed and followed up in the Department of Hematology, Sivas Cumhuriyet University Medical Faculty, and 33 healthy controls, were included in the study. Blood samples were collected from patients at the time of diagnosis and from individuals in the control group for hemogram and biochemistry tests and serum IL-17, IL-36α, IL-36β, and IL-36γ levels. Patients were divided into three groups, complete remission (CR), partial remission (PR), and progression according to interim positron emission tomography/computed tomography (PET/CT) results. Results: Serum IL-36α (p
- 30 April 2025
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 27 (1) , 23-28
Open AccessDetermination of Serum Interleukin-36 Alpha, Beta, Gamma, and Interleukin-17 Levels in Patients with Non-Hodgkin Lymphoma
Aim: Non-Hodgkin lymphoma (NHL) is a diverse group of hematologic cancers characterized by uncontrolled proliferation of lymphoid cells. This study aimed to evaluate the relationship between serum concentrations of interleukin-36 alpha (IL-36α), interleukin-36 beta (IL-36β), interleukin-36 gamma (IL-36γ), and interleukin-17 (IL-17), which play an important role in the immune system, in NHL patients and whether these cytokines can serve as potential biomarkers or therapeutic targets for NHL. Material and Methods: A total of 88 individuals, including 55 NHL patients diagnosed and followed up in the Department of Hematology, Sivas Cumhuriyet University Medical Faculty, and 33 healthy controls, were included in the study. Blood samples were collected from patients at the time of diagnosis and from individuals in the control group for hemogram and biochemistry tests and serum IL-17, IL-36α, IL-36β, and IL-36γ levels. Patients were divided into three groups, complete remission (CR), partial remission (PR), and progression according to interim positron emission tomography/computed tomography (PET/CT) results. Results: Serum IL-36α (p
- Open Access
- 7 February 2025
- Published by MediHealth Academy in Intercontinental Journal of Internal Medicine
- Vol. 3 (1) , 15-18
Epstein-Barr virus RNA percentage and its impact on prognosis in patients with diffuse large B-cell lymphoma
Aims: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphomas. This study aimed to investigate the impact of Epstein-Barr virus RNA (EBER) positivity on the prognosis of patients diagnosed with DLBCL. Methods: This retrospective study was conducted on 105 patients diagnosed with DLBCL at Sivas Cumhuriyet University Hospital between June 1, 2009, and May 31, 2022. Results: Of the 105 patients, 55.2% were male, and the mean age was 56.89 years. EBER positivity was detected in 4.8% of the patients. While 71% of EBER-negative patients achieved a complete response, overall survival and progression-free survival were shorter in EBER-positive patients. However, no significant relationship was observed between EBER positivity and prognostic indices (IPI, R-IPI, NCCN-IPI). Conclusion: The findings of this study indicate that EBER positivity could act as a prognostic indicator, given its association with unfavorable survival rates and diminished response to treatment in individuals with DLBCL.
- 7 February 2025
- Published by MediHealth Academy in Intercontinental Journal of Internal Medicine
- Vol. 3 (1) , 15-18
Open AccessEpstein-Barr virus RNA percentage and its impact on prognosis in patients with diffuse large B-cell lymphoma
Aims: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphomas. This study aimed to investigate the impact of Epstein-Barr virus RNA (EBER) positivity on the prognosis of patients diagnosed with DLBCL. Methods: This retrospective study was conducted on 105 patients diagnosed with DLBCL at Sivas Cumhuriyet University Hospital between June 1, 2009, and May 31, 2022. Results: Of the 105 patients, 55.2% were male, and the mean age was 56.89 years. EBER positivity was detected in 4.8% of the patients. While 71% of EBER-negative patients achieved a complete response, overall survival and progression-free survival were shorter in EBER-positive patients. However, no significant relationship was observed between EBER positivity and prognostic indices (IPI, R-IPI, NCCN-IPI). Conclusion: The findings of this study indicate that EBER positivity could act as a prognostic indicator, given its association with unfavorable survival rates and diminished response to treatment in individuals with DLBCL.
- Open Access
- 22 January 2025
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 34 (1) , 26-30
Relationship of Plasma Cell Infiltration Rates with 18F-FDG PET/CT Data and Hematological Parameters in Multiple Myeloma
Relationship of Plasma Cell Infiltration Rates with 18F-FDG PET/CT Data and Hematological Parameters in Multiple Myeloma - Molecular Imaging and Radionuclide Therapy
- 22 January 2025
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 34 (1) , 26-30
Open AccessRelationship of Plasma Cell Infiltration Rates with 18F-FDG PET/CT Data and Hematological Parameters in Multiple Myeloma
Relationship of Plasma Cell Infiltration Rates with 18F-FDG PET/CT Data and Hematological Parameters in Multiple Myeloma - Molecular Imaging and Radionuclide Therapy
- Open Access
- 1 January 2025
- Published by Kare Publishing in Journal of Clinical Practice and Research
- Vol. 47 (4) , 364-373
A bibliometric analysis of research on pregnancy and thrombocytopenia
Objective: Thrombocytopenia is defined as a platelet count <150 × 10⁹/L. Thrombocytopenia is a condition frequently encountered during pregnancy. We aimed to perform a bibliometric analysis of the literature on thrombocytopenia in pregnancy to identify research trends, leading contributors, and citation patterns. By analyzing scientific productivity, collaboration networks, and keyword co-occurrence, we aimed to map the development of the field and highlight gaps to guide future research. Materials and Methods: We included articles, reviews, and early view articles published in English on pregnancy and thrombocytopenia from the Web of Science database from 1972 to 2024. VOSviewer and R-bibliometrix were used for bibliometric analysis, revealing the distribution of leading research countries, institutions, journals, authors, and keywords. Results: The bibliometric analysis on pregnancy and thrombocytopenia included 2,149 publications across 691 journals, authored by 8,959 researchers. The United States led with 544 publications. The top three journals were American Journal of Obstetrics and Gynecology, Obstetrics and Gynecology, and Transfusion. Kaplan C, Husebekk A, and Skogen B were identified as the most cited authors in this field. Conclusion: This bibliometric analysis on pregnancy and thrombocytopenia highlights the scientific productivity in this field and serves as an important resource for identifying potential areas for future research and collaborations. The expansion of research in this domain will contribute to the accumulation of knowledge and enhance clinical applications.
- 1 January 2025
- Published by Kare Publishing in Journal of Clinical Practice and Research
- Vol. 47 (4) , 364-373
Open AccessA bibliometric analysis of research on pregnancy and thrombocytopenia
Objective: Thrombocytopenia is defined as a platelet count <150 × 10⁹/L. Thrombocytopenia is a condition frequently encountered during pregnancy. We aimed to perform a bibliometric analysis of the literature on thrombocytopenia in pregnancy to identify research trends, leading contributors, and citation patterns. By analyzing scientific productivity, collaboration networks, and keyword co-occurrence, we aimed to map the development of the field and highlight gaps to guide future research. Materials and Methods: We included articles, reviews, and early view articles published in English on pregnancy and thrombocytopenia from the Web of Science database from 1972 to 2024. VOSviewer and R-bibliometrix were used for bibliometric analysis, revealing the distribution of leading research countries, institutions, journals, authors, and keywords. Results: The bibliometric analysis on pregnancy and thrombocytopenia included 2,149 publications across 691 journals, authored by 8,959 researchers. The United States led with 544 publications. The top three journals were American Journal of Obstetrics and Gynecology, Obstetrics and Gynecology, and Transfusion. Kaplan C, Husebekk A, and Skogen B were identified as the most cited authors in this field. Conclusion: This bibliometric analysis on pregnancy and thrombocytopenia highlights the scientific productivity in this field and serves as an important resource for identifying potential areas for future research and collaborations. The expansion of research in this domain will contribute to the accumulation of knowledge and enhance clinical applications.
- 30 June 2024
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 45 (2) , 263-267
Determination of Serum Cathepsin G Level in Patients with Multiple Myeloma
Multiple myeloma is a hematological malignancy identified by bone marrow infiltration of clonal plasma cells. It is still not a curable disease under current conditions. Cathepsin G is a serine protease playing a role in inflammation that is present in the azurophilic granules of neutrophils. It is known that there is a relationship between Cathepsin G and chronic inflammatory diseases and tumors. The goal of the study is to define its role in multiple myeloma. In the study, 33 patients newly diagnosed with MM who were never received treatment and 33 control subjects were included. Basic laboratory parameters and Cathepsin G levels were examined both in the myeloma patient group and control group. While the serum CathG level in the control group is 22.84 ng/mL, the serum CathG level of the MM patient group is 10.77 ng/mL. Serum CathG level in the control group is statistically significantly higher than the MM patient group. The aim of the present study is to contribute to the literature in hematological malignancies, to figure out the role of Cathepsin G in multiple myeloma, and to open a door to new treatment options for multiple myeloma, which is an incurable disease, yet.
- 30 June 2024
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 45 (2) , 263-267
Determination of Serum Cathepsin G Level in Patients with Multiple Myeloma
Multiple myeloma is a hematological malignancy identified by bone marrow infiltration of clonal plasma cells. It is still not a curable disease under current conditions. Cathepsin G is a serine protease playing a role in inflammation that is present in the azurophilic granules of neutrophils. It is known that there is a relationship between Cathepsin G and chronic inflammatory diseases and tumors. The goal of the study is to define its role in multiple myeloma. In the study, 33 patients newly diagnosed with MM who were never received treatment and 33 control subjects were included. Basic laboratory parameters and Cathepsin G levels were examined both in the myeloma patient group and control group. While the serum CathG level in the control group is 22.84 ng/mL, the serum CathG level of the MM patient group is 10.77 ng/mL. Serum CathG level in the control group is statistically significantly higher than the MM patient group. The aim of the present study is to contribute to the literature in hematological malignancies, to figure out the role of Cathepsin G in multiple myeloma, and to open a door to new treatment options for multiple myeloma, which is an incurable disease, yet.
- 30 April 2024
- Published by Cumhuriyet University in Cumhuriyet Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 9 (1) , 40-47
Determination of the Knowledge Level of Nurses and Midwives Working at A University Hospital About Transfusion of Blood and Blood Products
OBJECTIVES: Blood transfusion is actually a tissue transplant and the possible complications are of vital importance. Thus, the healthcare personnel, who will perform the transfusion, should be trained in this regard. The aim of the present study is to determine the knowledge level of the nurses and midwives working at our hospital, about transfusion. BACKGROUND: Blood transfusion is one of the most common and risky procedures in hospitals. Therefore, complications related to blood transfusion should be known to all nurses and midwives. In this study, we found that the in-service training of the participants about transfusion and education levels is important in terms of determining the adequacy of this training. In addition to the level of education, knowledge and skills about transfusion have an important place. METHODS: A total of 534 healthcare professionals working at the Medical Faculty Hospital of Sivas Cumhuriyet University were included in the study. 514 (96.3%) of them were nurses and 20 (3.7%) were midwives. The questionnaire includes 9 questions about personal information, 9 questions on knowledge about pre-transfusion, 7 questions on the process of blood transfusion, 6 questions on blood and blood products, and 3 questions about the blood transfusion reaction. According to the scores taken in the questionnaire, the participants were divided in two sub-groups as group I (0-85) and group II (86-100). RESULTS: Mean age of the participants was 30.28±7.60 (18-55) years. In the questionnaire, correct answer rate of the participants was 93.28% in questions about nursing responsibilities before transfusion, 95.2% in questions about transfusion process, 94.5% in questions about identifying and managing transfusion reactions, and 71.71% in questions about knowledge levels of blood and blood products. CONCLUSION: Transfusion of blood and blood products is a complex process requiring a specific knowledge level. In general, it can be asserted that the nurses and midwives working at the hospital have good transfusion skills in parallel to their education, previous in-service transfusion training and their transfusion and reaction experiences.
- 30 April 2024
- Published by Cumhuriyet University in Cumhuriyet Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 9 (1) , 40-47
Determination of the Knowledge Level of Nurses and Midwives Working at A University Hospital About Transfusion of Blood and Blood Products
OBJECTIVES: Blood transfusion is actually a tissue transplant and the possible complications are of vital importance. Thus, the healthcare personnel, who will perform the transfusion, should be trained in this regard. The aim of the present study is to determine the knowledge level of the nurses and midwives working at our hospital, about transfusion. BACKGROUND: Blood transfusion is one of the most common and risky procedures in hospitals. Therefore, complications related to blood transfusion should be known to all nurses and midwives. In this study, we found that the in-service training of the participants about transfusion and education levels is important in terms of determining the adequacy of this training. In addition to the level of education, knowledge and skills about transfusion have an important place. METHODS: A total of 534 healthcare professionals working at the Medical Faculty Hospital of Sivas Cumhuriyet University were included in the study. 514 (96.3%) of them were nurses and 20 (3.7%) were midwives. The questionnaire includes 9 questions about personal information, 9 questions on knowledge about pre-transfusion, 7 questions on the process of blood transfusion, 6 questions on blood and blood products, and 3 questions about the blood transfusion reaction. According to the scores taken in the questionnaire, the participants were divided in two sub-groups as group I (0-85) and group II (86-100). RESULTS: Mean age of the participants was 30.28±7.60 (18-55) years. In the questionnaire, correct answer rate of the participants was 93.28% in questions about nursing responsibilities before transfusion, 95.2% in questions about transfusion process, 94.5% in questions about identifying and managing transfusion reactions, and 71.71% in questions about knowledge levels of blood and blood products. CONCLUSION: Transfusion of blood and blood products is a complex process requiring a specific knowledge level. In general, it can be asserted that the nurses and midwives working at the hospital have good transfusion skills in parallel to their education, previous in-service transfusion training and their transfusion and reaction experiences.